Reduced IL-7 Responsiveness Defined by Signal Transducer and Activator of Transcription 5 Phosphorylation in T Cells May Be a Marker for Increased Risk of Developing Cytomegalovirus Disease in Patients after Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 1, 2014, Pages 128-132

  Pérez Bercoff, Lena ^a,b   Vudattu, Nalini K ^c   Byrareddy, Siddappa N ^d   Mattsson, Jonas ^b   Maeurer, Markus ^a,b   Ljungman, Per ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytomegalovirus; Graft versus host disease; HSCT; Interleukin 2; Interleukin 7; Signal transducer and activator of transcription 5 (STAT5)

Indexed keywords

ANTIVIRUS AGENT; INTERLEUKIN 2; INTERLEUKIN 7; STAT5 PROTEIN;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE MARKER; ENGRAFTMENT; GAMMA DELTA T LYMPHOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INFECTION RISK; LONGITUDINAL STUDY; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REPLICATION;

CYTOMEGALOVIRUS; GRAFT-VERSUS-HOST DISEASE; HSCT; INTERLEUKIN-2; INTERLEUKIN-7; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 5 (STAT5);

ADULT; BIOLOGICAL MARKERS; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-2; INTERLEUKIN-7; MALE; PHOSPHORYLATION; PROSPECTIVE STUDIES; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS; VIRAL LOAD; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84890944467     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.006     Document Type: Article

References (28)

1. Ljungman P., Brand R. Factors influencing cytomegalovirus seropositivity in stem cell transplant patients and donors. Haematologica 2007, 92:1139-1142.
2. Ljungman P., Perez-Bercoff L., Jonsson J., et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 2006, 91:78-83.
3. Boeckh M., Leisenring W., Riddell S.R., et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: Importance of viral load and T-cell immunity. Blood 2003, 101:407-414.
4. Boeckh M., Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood 2009, 113:5711-5719.
5. Weseslindtner L., Kerschner H., Steinacher D., et al. Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients. Am J Transplant 2012, 12:2172-2180.
6. Gratama J.W., Boeckh M., Nakamura R., et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: A prospective multicenter study. Blood 2010, 116:1655-1662.
7. Ljungman P., de la Camara R., Cordonnier C., et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008, 42:227-240.
8. Reusser P., Einsele H., Lee J., et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002, 99:1159-1164.
9. Green M.L., Leisenring W., Stachel D., et al. Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012, 18:1687-1699.
10. Mackall C.L., Fry T.J., Gress R.E. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011, 11:330-342.
11. Kemp R.A., Pearson C.F., Cornish G.H., Seddon B.P. Evidence of STAT5-dependent and -independent routes to CD8 memory formation and a preferential role for IL-7 over IL-15 in STAT5 activation. Immunol Cell Biol 2010, 88:213-219.
12. Lin J.X., Migone T.S., Tsang M., et al. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 1995, 2:331-339.
13. Rosenthal L.A., Winestock K.D., Finbloom D.S. IL-2 and IL-7 induce heterodimerization of STAT5 isoforms in human peripheral blood T lymphoblasts. Cell Immunol 1997, 181:172-181.
14. Pallard C., Stegmann A.P., van Kleffens T., et al. Distinct roles of the phosphatidylinositol 3-kinase and STAT5 pathways in IL-7-mediated development of human thymocyte precursors. Immunity 1999, 10:525-535.
15. Vudattu N.K., Magalhaes I., Schmidt M., et al. Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer 2007, 121:1512-1519.
16. Bellistri G.M., Casabianca A., Merlini E., et al. Increased bone marrow interleukin-7 (IL-7)/IL-7R levels but reduced IL-7 responsiveness in HIV-positive patients lacking CD4+ gain on antiviral therapy. PloS one 2010, 5:e15663.
17. Schluns K.S., Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003, 3:269-279.
18. Avetisyan G., Aschan J., Hagglund H., et al. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 2007, 40:865-869.
19. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34:1094-1097.
20. Vudattu N.K., Kuhlmann-Berenzon S., Khademi M., et al. Increased numbers of IL-7 receptor molecules on CD4+CD25-CD107a+ T-cells in patients with autoimmune diseases affecting the central nervous system. PloS one 2009, 4:e6534.
21. Ozdemir E., St John L.S., Gillespie G., et al. Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 2002, 100:3690-3697.
22. Omar H., Ahmed R., Rane L., et al. Decreased IL-7 signaling in T cells from patients with PTLD after allogeneic HSCT. JImmunother 2011, 34:390-396.
23. Macchia I., Gauduin M.C., Kaur A., Johnson R.P. Expression of CD8alpha identifies a distinct subset of effector memory CD4+ T lymphocytes. Immunology 2006, 119:232-242.
24. Oevermann L., Lang P., Feuchtinger T., et al. Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. Ann N Y Acad Sci 2012, 1266:161-170.
25. Scheper W., van Dorp S., Kersting S., et al. γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia. Leukemia 2013, 27:1328-1338.
26. Sinha M.L., Fry T.J., Fowler D.H., et al. Interleukin 7 worsens graft-versus-host disease. Blood 2002, 100:2642-2649.
27. Dean R.M., Fry T., Mackall C., et al. Association of serum interleukin-7 levels with the development of acute graft-versus-host disease. JClin Oncol 2008, 26:5735-5741.
28. Napolitano L.A., Grant R.M., Deeks S.G., et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: Implications for T-cell homeostasis. Nature Med 2001, 7:73-79.